Our Research
Discover our recent findings, catch up with news, and review in-depth resources.
Advancing Immunoassay Method Development and Automation at Resolian
Precision, efficiency, and scientific expertise are essential in today’s fast-moving bioanalytical landscape. At Resolian, we’ve taken a bold step forward—restructuring teams, refining method development processes, and strategically implementing automation to enhance service delivery.
De-risk Your Drug Development with Resolian’s Polymorph Screening Expertise
Polymorph screening is a process that identifies and characterizes the crystalline forms of a compound, and then selects the best form for development.
Assessing and controlling the crystalline form of your material plays a crucial role in all the stages of the product lifecycle.
Foreign Particulate Matter Solutions for Vaccine Safety
Foreign particulate matter (FPM) in vaccines poses risks to product safety, patient health, and regulatory compliance. With stringent guidelines from agencies like the FDA and EMA, identifying and controlling contaminants is essential to maintaining trust and ensuring safety.
Oligonucleotide Therapeutics Podcast
Min Meng, Chief Operations Officer at Resolian. The interview focuses on the bioanalysis of oligonucleotide therapeutics, a rapidly evolving area in drug development. Min Meng, with 20+ years of experience in this field, provides valuable insights into the unique challenges and advantages of these therapies.
Sustainability in Extractables and Leachables
Resolian is committed to reducing its environmental impact wherever feasibly possible.
Recently the Extractables and Leachables team at the Fordham lab of Analytical Sciences aimed to implement and evaluate green chemistry principles.
Australian Clinical Trials Podcast
In this visual podcast we explore why Australia is an attractive destination for early-phase clinical trials, highlighting the benefits of speed, quality, and cost-effectiveness.
The expert panel discussion delves into Australia’s unique regulatory pathways, the R&D tax incentives, operational logistics, and how early-phase data supports global drug development.